Skip to main content

PFIZER INC

For the period ended Sep 29, 2024. Filed Nov 4, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 29, 2024 · Filed Nov 4, 2024

PFE$29.36+0.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Provision/(Benefit) for Taxes on Income/(Loss)

Three Months EndedNine Months Ended
(MILLIONS)September 29,2024October 1,2023%ChangeSeptember 29,2024October 1,2023%Change
Provision/(benefit) for taxes on income/(loss)$234$(964)*$393$(320)*
Effective tax rate on continuing operations5.0%28.8%4.9%(6.2)%

For information about our effective tax rate and the events and circumstances contributing to the changes between periods, as well as details about discrete elements that impacted our tax provisions, see Note 5.

Cash paid for income taxes, net of refunds, consisted of:
Year Ended December 31,
(MILLIONS)202320222021
United States$1,923$3,867$4,455
International1,2244,0002,972
Total$3,147$7,867$7,427

Changes in Tax Laws––Many countries outside the U.S. have enacted legislation for global minimum taxation resulting from the Organization for Economic Co-operation and Development’s (OECD) Base Erosion and Profit Shifting “Pillar 2” project. The EU has approved a directive requiring member states to incorporate the OECD provisions into their respective domestic laws, and countries outside the EU are also enacting the provisions into their domestic law. The provisions are generally effective for Pfizer in 2024, though significant details and guidance around the provisions are still pending. Income tax expense could be adversely affected as the legislation becomes effective in countries in which we do business, and such impact could be material to our results of operations. We continue to monitor pending OECD guidance and legislation enactment and implementation by individual countries.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.